MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Cerrado

SectorSanidad

123.73 2.37

Resumen

Variación precio

24h

Actual

Mínimo

123.53

Máximo

124.48

Métricas clave

By Trading Economics

Ingresos

-7.9B

1.3B

Ventas

-616M

10B

P/B

Media del Sector

17.147

39.857

BPA

1.09

Rentabilidad por dividendo

1.74

Margen de beneficios

12.792

Empleados

114,000

EBITDA

-324M

2.7B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+17.79% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.74%

2.42%

Próximas Ganancias

15 oct 2025

Fecha Próximo Dividendo

15 ago 2025

Próxima Fecha de Ex Dividendo

14 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.9B

230B

Apertura anterior

121.36

Cierre anterior

123.73

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

138 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Abbott Laboratories Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jul 2025, 12:10 UTC

Ganancias

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16 abr 2025, 16:21 UTC

Ganancias

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 abr 2025, 12:14 UTC

Ganancias

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17 jul 2025, 13:14 UTC

Ganancias

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 jul 2025, 12:16 UTC

Ganancias

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 jul 2025, 11:32 UTC

Ganancias

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 jul 2025, 11:32 UTC

Ganancias

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 jul 2025, 11:31 UTC

Ganancias

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Sales $11.14B >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Net $1.78B >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 jul 2025, 11:30 UTC

Ganancias

Abbott Labs 2Q EPS $1.01 >ABT

17 jul 2025, 09:08 UTC

Acciones populares

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1 jul 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16 abr 2025, 15:09 UTC

Charlas de Mercado

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 abr 2025, 14:17 UTC

Ganancias

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 abr 2025, 11:34 UTC

Ganancias

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 abr 2025, 11:33 UTC

Ganancias

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 abr 2025, 11:32 UTC

Ganancias

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 abr 2025, 11:32 UTC

Ganancias

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 abr 2025, 11:31 UTC

Ganancias

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 abr 2025, 11:30 UTC

Ganancias

Abbott Reaffirms Full-Yr Guidance

16 abr 2025, 11:30 UTC

Ganancias

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 abr 2025, 11:30 UTC

Ganancias

Abbott Labs 1Q Sales $10.36B >ABT

16 abr 2025, 11:30 UTC

Ganancias

Abbott Labs 1Q Net $1.33B >ABT

Comparación entre iguales

Cambio de precio

Abbott Laboratories previsión

Precio Objetivo

By TipRanks

17.79% repunte

Estimación a 12 Meses

Media 145.67 USD  17.79%

Máximo 159 USD

Mínimo 135 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Abbott Laboratories Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

16

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

132.82 / 134.43Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

138 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.